Research & Innovation
Publications
Pathological complete response rates comparing 3 versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer.
PMU Authors
Roland Reitsamer, Florentia Peintinger, Wolfgang Hitzl
All Authors
Roland Reitsamer, Florentia Peintinger, Eva Prokop, Wolfgang Hitzl
Journal association
ANTI-CANCER DRUGS
Abstract
We are sorry. The full text is not available.
Keywords
TUMORS, WOMEN, CARCINOMA, SURGICAL ADJUVANT BREAST, PREOPERATIVE CHEMOTHERAPY, DOXORUBICIN, B-18